Search for: "Amgen Inc. v. Sanofi"
Results 21 - 40
of 105
Sorted by Relevance
|
Sort by Date
18 May 2023, 12:15 pm
Earlier today, the United States Supreme Court issued its decision in Amgen, Inc. v. [read post]
18 May 2023, 12:15 pm
Earlier today, the United States Supreme Court issued its decision in Amgen, Inc. v. [read post]
9 Aug 2018, 5:16 pm
” Amgen Inc. v. [read post]
5 Jan 2023, 10:43 am
Supreme Court on the question presented by Amgen Inc. v. [read post]
5 Jan 2023, 10:43 am
Supreme Court on the question presented by Amgen Inc. v. [read post]
10 Sep 2023, 9:15 am
The Supreme Court’s decision in Amgen Inc. v. [read post]
10 Sep 2023, 9:15 am
The Supreme Court’s decision in Amgen Inc. v. [read post]
20 Sep 2023, 9:39 am
by Dennis Crouch Baxalta Inc. v. [read post]
11 Jan 2024, 12:59 pm
Background on Amgen v. [read post]
22 May 2023, 4:59 pm
On May 18, 2023, the Supreme Court of the United States issued a unanimous decision in the case of Amgen Inc. et al. v. [read post]
17 May 2023, 9:00 pm
Sanofi, Andy Warhol Foundation for Visual Arts, Inc. v. [read post]
23 Oct 2015, 2:58 pm
Robinson in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
23 Mar 2023, 11:41 am
In Amgen Inc. v. [read post]
6 Oct 2017, 2:34 pm
Finding for Sanofi, the court held the sentence to be improper, relying heavily on its decision in Centocor Ortho Biotech, Inc. v. [read post]
